Molecule to cure. Fast.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Because humanity needs solutions, fast.
Watch our video
Welcome
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
Services
At Quotient Sciences, we have streamlined the drug development process by providing pre-formulation screening, formulation development & optimization, first-in-human trials, and clinical & commercial manufacturing services all at one CDMO, allowing us to support drug programs from candidate selection through commercial supply.
Latest updates
-
NewsEvecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression TreatmentA drug development partnership between Evecxia Therapeutics and Quotient Sciences has resulted in the successful delivery of a Phase 1 clinical testing program for Evecxia’s drug candidate EVX-101, which is in development for major depressive disorder (MDD).
-
Oct 24Live SeminarAAPS 2023 Seminar: How to Accelerate Drug Product Optimization Using Translational Pharmaceutics®During AAPS 2023, we will be hosting a seminar entitled, 'How to Accelerate Drug Product Optimization Using Translational Pharmaceutics®'. There are limited spaces available. Register today.
-
WebinarAccelerating formulation development to address poor drug solubility using Translational PharmaceuticsThis webinar examines how to accelerate formulation development in order to address poor drug solubility using Translational Pharmaceutics, showcasing examples of how Translational Pharmaceutics has been used across all phases of clinical development:
-
Case StudiesEndevica Case Study - Peptide Program using Translational PharmaceuticsEndevica Bio is developing TCMCB07 as a novel synthetic peptide product for the potential treatment of cachexia. Read how they leveraged the Quotient Sciences Translational Pharmaceutics platform for this program.
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.